MIAMI, FL / ACCESS Newswire / August 6, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced that it has reached an agreement in principle to acquire a portfolio of intellectual property valued at approximately $10 million.

The proposed transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by all parties, and review by their respective legal counsel. As a result, there can be no assurance that the acquisition will ultimately be completed on the terms currently contemplated, or at all.

The intellectual property is expected to strengthen AimwellBio's long-term strategic position and support the Company's mission of building trusted, verified intelligence infrastructure for healthcare and life sciences.

"Reaching an agreement in principle is an important milestone," said John Morgan, Chief Executive Officer of Aimwell Partners Inc. "While there is still meaningful work to be completed through due diligence and legal review, we believe this proposed acquisition has the potential to significantly enhance the value and capabilities of the AimwellBio platform. We look forward to sharing additional details after the transaction has closed."

To protect the integrity of the ongoing process, the Company will not disclose the nature of the intellectual property or additional transaction terms until the acquisition has been completed. Following closing, Aimwell expects to provide investors with comprehensive information regarding the acquired assets, their strategic importance, and anticipated integration into the Company's platform.

The Company will continue to provide updates as appropriate and in accordance with applicable disclosure requirements.

About Aimwell Partners Inc.

Aimwell Partners Inc. (OTC:AIMN) is the parent company of AimwellBio, a healthcare intelligence platform focused on combining verified information with qualified professional expertise. Through its growing network of physicians, scientists, researchers, and industry professionals, AimwellBio is developing infrastructure designed to improve confidence, transparency, and decision-making across healthcare, life sciences, regulatory affairs, and investment research.

For more information, visit www.aimwellbio.com.

Investor Relations

John Morgan
Chief Executive Officer
Aimwell Partners Inc.
Email: corporate@aimwellbio.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding the proposed acquisition of intellectual property, the anticipated value of the assets, expected strategic benefits, the completion of due diligence, execution of definitive agreements, and future business plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including the possibility that the transaction is not completed, delays in closing, regulatory or contractual issues, market conditions, financing considerations, and other factors beyond the Company's control. Readers should not place undue reliance on forward-looking statements, which speak only as of the date of this release.

SOURCE: Aimwell Partners Inc.